Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Papillomavirus Infections 11 Warts 2 Uterine Cervical Neoplasms 2 Uterine Cervical Dysplasia 2 HIV Infections 2 Condylomata Acuminata 2 Acquired Immunodeficiency Syndrome 2 Neoplasms 1 Myelodysplastic Syndromes 1 Lymphoma, Large B-Cell, Diffuse 1 Leukemia, Myeloid, Acute 1 Infections 1 Human Papillomavirus-Related Cervical Carcinoma 1 Human Papillomavirus-Related Carcinoma 1 High Grade Anal Canal Intraepithelial Neoplasia 1 Hematologic Neoplasms 1 Cancer Survivor 1

Interventions

pembrolizumab 180 Gemcitabine 168 Paclitaxel 150 Carboplatin 134 Bevacizumab 126 Cisplatin 113 Docetaxel 112 Cyclophosphamide 109 Exercise 97 Nivolumab 93 Fluorouracil 88 Capecitabine 85 Dexamethasone 81 Irinotecan 74 Radiotherapy 68 Oxaliplatin 68 Pemetrexed 66 Standard of Care 64 Leucovorin 63 Cetuximab 59 Sorafenib 53 Erlotinib Hydrochloride 53 Drug Therapy 53 Blood Specimen Collection 51 Doxorubicin 50 atezolizumab 48 trametinib 47 Ipilimumab 47 Albumin-Bound Paclitaxel 44 130-nm albumin-bound paclitaxel 42

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasms × Human Papillomavirus Recombinant Vaccine nonavalent × Clear all

NCT06658405 2026-03-18

HPV2

Centre Oscar Lambret

Phase 2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡